Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease

Trial Profile

Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs Rivastigmine (Primary) ; Rivastigmine
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms IDEAL
  • Sponsors Novartis
  • Most Recent Events

    • 01 Oct 2016 Results of population pharmacokinetic analysis, assessing effects of renal impairment on steady-state plasma concentrations of rivastigmine and its metabolite NAP226-90 after rivastigmine patch and capsule treatment in patients with Alzheimer's disease, published in Drugs and Aging Journal.
    • 28 Sep 2016 Results of population pharmacokinetic analysis, assessing effects of renal impairment on steady-state plasma concentrations of rivastigmine and its metabolite NAP226-90 after rivastigmine patch and capsule treatment in patients with Alzheimer's disease, published in Drugs and Aging Journal.
    • 15 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top